CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Emmaus Life Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Emmaus Life Sciences Inc
21250 HAWTHORNE BOULEVARD, SUITE 800
Phone: (310) 214-0065p:310 214-0065 TORRANCE, CA  90503  United States Ticker: EMMAEMMA
Business Summary
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. Its lead product, Endari (prescription grade L-glutamine oral powder) helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. The Company has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Chief Operating Officer Willis C.Lee 62 7/15/2024 5/1/2011
Chief Financial Officer YasushiNagasaki 55 9/1/2020 7/17/2019
Senior Vice President - Medical Affairs, Clinical, Regulatory CharlesStark 67 11/23/2021 11/23/2021
3 additional Officers and Directors records available in full report.

Business Names
Business Name
CNSO
CNSOD
EMMA
8 additional Business Names available in full report.

General Information
Number of Employees: 51 (As of 12/31/2023)
Outstanding Shares: 63,865,571 (As of 8/12/2024)
Shareholders: 391
Stock Exchange: OTC
Federal Tax Id: 870419387
Fax Number: (310) 214-0075


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024